Stay updated with breaking news from Exscientia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Fast and accurate generative AI design of novel antibodies extends Exscientia's capabilities beyond small molecules Sequencing paired human antibody data to create better AI models for antibody
Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in November: BofA Securities 2022 A.I. and Disruptive
Combines precision oncology platform with single-cell sequencing and transcriptomics with aim to select patients most likely to benefit from GTAEXS-617 therapy Confirmed and identified CDK7-specific
Findings support deep learning ex vivo drug screening with patient tissue as a promising tool to identify effective, individual treatments in advanced blood cancer over conventional methods Custom
Exscientia plc (Nasdaq: EXAI) today announced that Caroline Rowland has joined Exscientia as Chief People Officer. In this newly created role, she will lead Exscientia's People (human resources) and